Genetically engineered Newcastle disease virus for malignant melanoma therapy. Jun 2009 - Gene Ther.; 16(6):1476-5462 [PMID:19242529] [Zamarin D] [Vigil A] [Kelly K] [García-Sastre A] [Fong Y]
Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Apr 2009 - Mol. Ther.; 17(4):1525-0024 [PMID:19209145] [Zamarin D] [Martínez-Sobrido L] [Kelly K] [Mansour M] [Sheng G] [Vigil A] [García-Sastre A] [Palese P] [Fong Y]
Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Okt 2008 - Mol. Ther.; 16(11):1525-0024 [PMID:18714310] [Vigil A] [Martinez O] [Chua MA] [García-Sastre A]
Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Sep 2007 - Cancer Res.; 67(17):0008-5472 [PMID:17804743] [Vigil A] [Park MS] [Martinez O] [Chua MA] [Xiao S] [Cros JF] [Martínez-Sobrido L] [Woo SL] [García-Sastre A]
